Athyrium Opportunities IV Acquisition 2 LP 13D and 13G filings for RVL Pharmaceuticals plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-10-13 5:28 pm Unchanged | 2023-10-12 | 13D | RVL Pharmaceuticals plc RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% | 0 (Unchanged) | Filing |
| 2023-09-05 07:45 am Unchanged | 2023-09-05 | 13D | RVL Pharmaceuticals plc RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 13.100% | 0 (Unchanged) | Filing |
| 2022-08-11 3:53 pm Purchase | 2022-08-08 | 13G | RVL Pharmaceuticals plc RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 14,600,444 14.750% | 6,262,242 (+75.10%) | Filing |
| 2021-10-22 4:27 pm Purchase | 2021-10-12 | 13G | RVL Pharmaceuticals plc RVLPQ | Athyrium Opportunities IV Acquisition 2 LP | 8,338,202 9.990% | 8,338,202 (New Position) | Filing |